This article is freely available to all

Article Abstract

Assessment of treatment response in panic disorder is complicated by the multidimensional aspectsof panic disorder and agoraphobia, the short-term benefits from nonspecific aspects of treatment,and placebo response. Response to treatment with psychological and pharmacologic treatmentsof panic disorder is reviewed in this context. The experience of several Phase III studies of fluvoxaminein the treatment of panic disorder is examined as an illustrative example. When the response toplacebo or comparison treatment in a study is high, no conclusion can be drawn about the true efficacyof the active treatment.